<DOC>
	<DOC>NCT01028521</DOC>
	<brief_summary>A first time in man, phase I study to assess the safety, tolerability and pharmacokinetics of single ascending doses of CM3.1-AC100 in healthy male volunteers.</brief_summary>
	<brief_title>First in Man Clinical Study to Investigate Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of CM3.1-AC100</brief_title>
	<detailed_description />
	<criteria>Provision of signed and dated informed consent prior to any study specific procedures Body weight between 60.0 to 100.0 kg (both inclusive) and BMI 19 to 29.9 kg/m2 (both inclusive) Judged as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination) Any history or presence of a clinically relevant disease as judged to be relevant by the Investigator Blood donation within 3 month before administration of the IP Have a history of hypersensitivity to the IP or any of the excipients or to medicinal products with similar chemical structures</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>First time in man, safety study, Cm3.1-AC100</keyword>
	<keyword>Male volunteer aged 18 to 50 years at Screening</keyword>
</DOC>